CALIBRE - Participants Information



CALIBRE - Carvedilol versus variceal band ligation in primary prevention of variceal bleeding in liver cirrhosis  


Thankyou to all our collaborators for the hard work that has been put into delivering CALIBRE.

Please note BCTU will be closed between Monday 19th December 2022 and Monday 2nd January 2023 (inclusive). During this time, please continue to report any SAEs to the CALIBRE trial inbox,, which will be monitored for this reason only.


Message from Chief Investigator, Professor Dhiraj Tripathi


Randomised controlled trial of carvedilol versus variceal band ligation in primary prevention of variceal bleeding in liver cirrhosis.

Sponsor:   University of Birmingham

Chief Investigator:   Dr. Dhiraj Tripathi

Coordinating Centre:   Birmingham Clinical Trials Unit

Funder:   National Institute for Health Research (NIHR)

                 Health and Technologies Assessment (HTA) Programme

Aim of Study

To investigate the clinical and cost-effectiveness of carvedilol versus variceal band ligation in patients with cirrhosis and medium to large oesophageal varices that have not bled.


Acute NHS Trusts across the UK.

Target population

Adult patients with liver cirrhosis as defined clinically, radiologically (USS and transient elastography), or histology and medium varices (Grade II varices that do not flatten on air insufflation and do not occlude the lumen) and large varices (Grade III varices which are larger than Grade II varices and occupy the whole lumen) that have never bled as defined in the BSG guidelines will be eligible to be recruited.


Patients will be randomised to treatment with variceal band ligation or 12.5 mg carvedilol once daily.